AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32228776 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Number of subjects: 29
Study 35481583 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored physiotherapeutic intervention (three personalized 1-hour sessions with a physiotherapist)
Number of subjects: 69
Study 35481583 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored physiotherapeutic intervention
Number of subjects: 69
Study 35481583 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 69
Study 32086657 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers and Babies (MB) intervention led by paraprofessionals
Number of subjects: 0
Study 32086657 — intervention group
Group type: COMPARATOR
Intervention: Mothers and Babies (MB) intervention led by mental health professionals
Number of subjects: 0
Study 34424387 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior antiglide plate with additional anteroposterior cannulated headless compression screws (group antiGP + HCS)
Number of subjects: 14
Study 34424387 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral distal humerus locking plate with lateral extension (group PLP)
Number of subjects: 14
Study 34759112 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid-enriched milk beverage (297 mg docosahexaenoic acid and 137 mg eicosapentaenoic acid)
Number of subjects: 0
Study 34759112 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid-enriched milk beverage
Number of subjects: 0
Study 32708893 — intervention group
Group type: EXPERIMENTAL
Intervention: PE‐5 (75 g glucose ingested 5 min after exercise)
Number of subjects: 8
Study 32708893 — intervention group
Group type: EXPERIMENTAL
Intervention: PE‐30 (75 g glucose ingested 30 min after exercise)
Number of subjects: 8
Study 32708893 — intervention group
Group type: COMPARATOR
Intervention: Control (Con - 75 g glucose without exercise)
Number of subjects: 8
Study 35689188 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsive Lifestyle Counselling (ILC)
Number of subjects: 165
Study 35689188 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 165
Study 33652128 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 0
Study 33652128 — intervention group
Group type: COMPARATOR
Intervention: Stretching and toning exercises (Control)
Number of subjects: 0
Study 35871234 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin plus ifosfamide (AI)
Number of subjects: 143
Study 35871234 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine plus docetaxel (GD)
Number of subjects: 143
Study 34162374 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential MV (n = 24)
Number of subjects: 44
Study 34162374 — intervention group
Group type: COMPARATOR
Intervention: Conventional MV (n = 20)
Number of subjects: 44
Study 32543290 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR combined with exercise (Exercise+IVR)
Number of subjects: 20
Study 32543290 — intervention group
Group type: COMPARATOR
Intervention: Exercise training (EG)
Number of subjects: 20
Study 35767837 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuman Systems Model (NSM) approach
Number of subjects: 62
Study 35767837 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62
Study 33454124 — intervention group
Group type: EXPERIMENTAL
Intervention: Henagliflozin (2.5-200 mg single ascending dose)
Number of subjects: 128
Study 33454124 — intervention group
Group type: EXPERIMENTAL
Intervention: Henagliflozin (1.25-100 mg multiple ascending dose for 10 days)
Number of subjects: 128
Study 35964133 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Contact CBT (MC-CBT)
Number of subjects: 240
Study 35964133 — intervention group
Group type: COMPARATOR
Intervention: Education comparator (EDU)
Number of subjects: 240
Study 34264520 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIME‐EHR
Number of subjects: 120
Study 34264520 — intervention group
Group type: COMPARATOR
Intervention: Standard EHR
Number of subjects: 120
Study 32894073 — intervention group
Group type: EXPERIMENTAL
Intervention: First trimester 2D and 3D VR ultrasound examination
Number of subjects: 2800
Study 32894073 — intervention group
Group type: COMPARATOR
Intervention: Care as usual: second trimester 2D advanced ultrasound examination
Number of subjects: 2800
Study 32894073 — intervention group
Group type: EXPERIMENTAL
Intervention: First trimester 3D VR ultrasound
Number of subjects: 2800
Study 35287254 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy dose >54 Gy
Number of subjects: 225
Study 35287254 — intervention group
Group type: COMPARATOR
Intervention: Thoracic radiotherapy dose ≤54 Gy
Number of subjects: 225
Study 35287254 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy dose >54 Gy in patients with underlying lung disease
Number of subjects: 225
Study 33475251 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐64565111 5.0 mg
Number of subjects: 195
Study 33475251 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐64565111 7.4 mg
Number of subjects: 195
Study 33475251 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐64565111 10.0 mg
Number of subjects: 195
Study 33475251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 33475251 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐64565111 (all doses)
Number of subjects: 195
Study 33475251 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐64565111 5.0 mg and 7.4 mg
Number of subjects: 195
Study 32385134 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 83
Study 32385134 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 83
Study 35782634 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-Assisted Therapy (AAT) - 8 sessions
Number of subjects: 33
Study 33389377 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led mobile phone voice call reminder
Number of subjects: 468
Study 33389377 — intervention group
Group type: COMPARATOR
Intervention: Voice call with health promotion message (Control)
Number of subjects: 468
Study 35482235 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnic hyperoxia (7% CO2, 50% O2)
Number of subjects: 20
Study 35482235 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnic hypoxia (7% CO2, 10% O2)
Number of subjects: 20
Study 35482235 — intervention group
Group type: COMPARATOR
Intervention: Isocapnic hypoxia (10% O2)
Number of subjects: 20
Study 35482235 — intervention group
Group type: COMPARATOR
Intervention: Isocapnic hyperoxia (peripheral chemoreflex inhibition)
Number of subjects: 20
Study 35482235 — intervention group
Group type: COMPARATOR
Intervention: Hypocapnic hyperoxia (central and peripheral chemoreflex inhibition)
Number of subjects: 20
Study 34205936 — intervention group
Group type: EXPERIMENTAL
Intervention: Green-colored glasses
Number of subjects: 24
Study 34205936 — intervention group
Group type: COMPARATOR
Intervention: Clear glasses
Number of subjects: 24
Study 33026638 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-form PPoD questionnaire (11 items)
Number of subjects: 803
Study 36163263 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoprecipitate (cryo) transfusion
Number of subjects: 0
Study 36163263 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (Fg-C; Riastap) transfusion
Number of subjects: 0
Study 33372103 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg two times per day and lactulose 25 mL two times per day
Number of subjects: 238
Study 33372103 — intervention group
Group type: COMPARATOR
Intervention: Placebo 550 mg two times per day and lactulose 25 mL two times per day
Number of subjects: 238
Study 33372103 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin and lactulose
Number of subjects: 238
Study 35820991 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 460
Study 35820991 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (Psy-Ed)
Number of subjects: 460
Study 34957801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) group with individualized exercise-based training at moderate intensity for 4 weeks after PM implantation.
Number of subjects: 27
Study 34957801 — intervention group
Group type: COMPARATOR
Intervention: Non-CR group (control) with no cardiac rehabilitation.
Number of subjects: 27
Study 34957801 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CR and non-CR)
Number of subjects: 27
Study 34922857 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedsharing
Number of subjects: 428
Study 34922857 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal perception of an infant sleep problem
Number of subjects: 428
Study 34922857 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal depressive symptoms
Number of subjects: 428
Study 34922857 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedsharing prevalence
Number of subjects: 428
Study 32966573 — intervention group
Group type: EXPERIMENTAL
Intervention: TDENV-PIV followed by TDENV-LAV
Number of subjects: 80
Study 32966573 — intervention group
Group type: COMPARATOR
Intervention: TDENV-LAV followed by TDENV-PIV
Number of subjects: 80
Study 32957009 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch
Number of subjects: 99
Study 32957009 — intervention group
Group type: COMPARATOR
Intervention: Lunch-omission
Number of subjects: 99
Study 35555247 — intervention group
Group type: EXPERIMENTAL
Intervention: TEMP (26°C)
Number of subjects: 15
Study 35555247 — intervention group
Group type: EXPERIMENTAL
Intervention: WARM (31°C)
Number of subjects: 15
Study 35555247 — intervention group
Group type: EXPERIMENTAL
Intervention: HOT (36°C)
Number of subjects: 15
Study 33858527 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative approach (psychoeducation, mindfulness training, functional remediation)
Number of subjects: 65
Study 33858527 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative approach
Number of subjects: 65
Study 33858527 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 65
Study 34265047 — intervention group
Group type: EXPERIMENTAL
Intervention: Belumosudil 200 mg daily
Number of subjects: 132
Study 34265047 — intervention group
Group type: EXPERIMENTAL
Intervention: Belumosudil 200 mg twice daily
Number of subjects: 132
Study 34265047 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 132
Study 34265047 — intervention group
Group type: EXPERIMENTAL
Intervention: Belumosudil (both dosages)
Number of subjects: 132
Study 32787892 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodophor solution
Number of subjects: 30
Study 32787892 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine solution
Number of subjects: 30
Study 37312098 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (3 sessions/week, 40 min/session for 12 weeks)
Number of subjects: 30
Study 37312098 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 30
Study 37312098 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 30
Study 32475838 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antidiabetic agents (OAD) including metformin, sitagliptin, or pioglitazone
Number of subjects: 75
Study 32475838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 34865232 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational, web-based resource to reduce negative insulin appraisals
Number of subjects: 35
Study 34865232 — intervention group
Group type: COMPARATOR
Intervention: Existing online information about insulin
Number of subjects: 35
Study 32092047 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-VG
Number of subjects: 60
Study 33610731 — intervention group
Group type: EXPERIMENTAL
Intervention: EPM-delivered KRAS siRNA (siKRAS)
Number of subjects: 0
Study 33610731 — intervention group
Group type: EXPERIMENTAL
Intervention: EPM-mediated introduction of wild-type (WT) p53 pDNA (pcDNA-p53)
Number of subjects: 0
Study 33610731 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous WT p53
Number of subjects: 0
Study 33218563 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis with aluminum chloride hexahydrate (ACH) gel
Number of subjects: 20
Study 33218563 — intervention group
Group type: COMPARATOR
Intervention: Tap water iontophoresis
Number of subjects: 20
Study 34757812 — intervention group
Group type: EXPERIMENTAL
Intervention: AAP + SOC
Number of subjects: 515
Study 34757812 — intervention group
Group type: COMPARATOR
Intervention: docetaxel + SOC
Number of subjects: 515
Study 34114980 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection combined with pelvic floor rehabilitation
Number of subjects: 0
Study 34114980 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor rehabilitation alone
Number of subjects: 0
Study 35331823 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care trauma‐focused cognitive behavioral therapy (SC‐TF‐CBT)
Number of subjects: 183
Study 35331823 — intervention group
Group type: COMPARATOR
Intervention: Trauma-focused cognitive behavioral therapy (TF-CBT)
Number of subjects: 183
Study 33199421 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic bowel resection combined with infliximab treatment
Number of subjects: 106
Study 33199421 — intervention group
Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 106
Study 35789217 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol throat spray containing cold-adapted cod trypsin (GCTS), administered six times daily at first sign of a common cold
Number of subjects: 0
Study 35789217 — intervention group
Group type: COMPARATOR
Intervention: Control group (nontreated)
Number of subjects: 0
Study 35789217 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol throat spray containing cold-adapted cod trypsin (GCTS)
Number of subjects: 0
Study 34022840 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital alcohol moderation intervention + Treatment as Usual (TAU)
Number of subjects: 156
Study 34022840 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 156
Study 32771299 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress balls during treatment (Group 1)
Number of subjects: 55
Study 32771299 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music during treatment (Group 2)
Number of subjects: 55
Study 32771299 — intervention group
Group type: COMPARATOR
Intervention: Standard of care only (Group 3, Control)
Number of subjects: 55
Study 35022886 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary collaborative hospice care (ICHC)
Number of subjects: 166
Study 35022886 — intervention group
Group type: COMPARATOR
Intervention: Life-sustaining treatment (LST)
Number of subjects: 166
Study 34774040 — intervention group
Group type: EXPERIMENTAL
Intervention: National Exercise Referral Scheme (NERS)
Number of subjects: 50
Study 32397748 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsolateral prefrontal cortex a‐tDCS (1.5 mA, 20 minutes, six sessions over two weeks)
Number of subjects: 39
Study 32397748 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary motor a‐tDCS (1.5 mA, 20 minutes, six sessions over two weeks)
Number of subjects: 39
Study 32397748 — intervention group
Group type: COMPARATOR
Intervention: Sham a‐tDCS (20 minutes, six sessions over two weeks)
Number of subjects: 39
Study 35544283 — intervention group
Group type: COMPARATOR
Intervention: MST+tDCSsham
Number of subjects: 25
Study 35544283 — intervention group
Group type: EXPERIMENTAL
Intervention: MST+tDCS
Number of subjects: 25
Study 34561419 — intervention group
Group type: EXPERIMENTAL
Intervention: Syngeneic HSCT (Syn)
Number of subjects: 26
Study 34561419 — intervention group
Group type: COMPARATOR
Intervention: Autologous HSCT (Auto)
Number of subjects: 26
Study 34561419 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic HSCT from HLA-matched sibling donor (MSD)
Number of subjects: 26
Study 34561419 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic HSCT from HLA-matched unrelated donor (MUD)
Number of subjects: 26
Study 35674507 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose quadrivalent influenza vaccine
Number of subjects: 0
Study 35674507 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose quadrivalent influenza vaccine
Number of subjects: 0
Study 32345132 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) for 12 weeks, 3 days/week, 10 repetitions at 70% 1RM
Number of subjects: 44
Study 32345132 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 44
Study 33152329 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-field lymphadenectomy (3-FL)
Number of subjects: 76
Study 33152329 — intervention group
Group type: COMPARATOR
Intervention: Two-field lymphadenectomy (2-FL)
Number of subjects: 76
Study 32879630 — intervention group
Group type: EXPERIMENTAL
Intervention: Households advocating latrine IEC by Health Extension Workers (HEWs)
Number of subjects: 756
Study 32879630 — intervention group
Group type: EXPERIMENTAL
Intervention: Households living in their private house
Number of subjects: 756
Study 32879630 — intervention group
Group type: EXPERIMENTAL
Intervention: Households with government employees
Number of subjects: 756
Study 32879630 — intervention group
Group type: EXPERIMENTAL
Intervention: Households with latrines made on slab floor
Number of subjects: 756
Study 32879630 — intervention group
Group type: EXPERIMENTAL
Intervention: Households with latrines constructed inside the household compound
Number of subjects: 756
Study 32879630 — intervention group
Group type: EXPERIMENTAL
Intervention: Households receiving latrine IEC by Women Development Armies (WDAs)
Number of subjects: 756
Study 35413856 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral training of the ipsilesional arm using Virtual Reality and Manipulation Training (VRMT) protocol, 3 one-hour sessions per week for 5 weeks.
Number of subjects: 120
Study 35413856 — intervention group
Group type: COMPARATOR
Intervention: Conventional intervention on the contralesional arm, 3 one-hour sessions per week for 5 weeks.
Number of subjects: 120
Study 33887147 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease of 0.1 mmol/L serum calcium
Number of subjects: 76226
Study 35444642 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ST) alone
Number of subjects: 0
Study 35444642 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms combined
Number of subjects: 0
Study 35444642 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall CD19+CD20+ B cells
Number of subjects: 0
Study 35444642 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19+CD20+CD27+ memory B cells
Number of subjects: 0
Study 35444642 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-dsDNA levels
Number of subjects: 0
Study 35444642 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement levels
Number of subjects: 0
Study 34453262 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.025% formulation 5
Number of subjects: 88
Study 34453262 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.025% formulation 13
Number of subjects: 88
Study 34453262 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05% cream (Control)
Number of subjects: 88
Study 34453262 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 88
Study 35758344 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational emotive family health therapy (12-session treatment programme)
Number of subjects: 88
Study 35758344 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 88
Study 32648398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangguitanxue acupuncture combined with suspension exercise therapy
Number of subjects: 100
Study 32648398 — intervention group
Group type: COMPARATOR
Intervention: Suspension exercise therapy
Number of subjects: 100
Study 36178534 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) therapy (100% oxygen, 240 kPa)
Number of subjects: 12
Study 36178534 — intervention group
Group type: COMPARATOR
Intervention: Control (21% oxygen, 240 kPa)
Number of subjects: 12
Study 34496170 — intervention group
Group type: EXPERIMENTAL
Intervention: Origanum dubium essential oil
Number of subjects: 34
Study 34496170 — intervention group
Group type: EXPERIMENTAL
Intervention: Origanum vulgare subsp. hirtum essential oil
Number of subjects: 34
Study 34496170 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 34
Study 34496170 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavandula angustifolia essential oil
Number of subjects: 34
Study 34893432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.25× minimum alveolar concentration)
Number of subjects: 8
Study 34893432 — intervention group
Group type: COMPARATOR
Intervention: Propofol (1.25× minimum infusion rate)
Number of subjects: 8
Study 34893432 — intervention group
Group type: COMPARATOR
Intervention: Alfaxalone (1.25× minimum infusion rate)
Number of subjects: 8
Study 32803010 — intervention group
Group type: EXPERIMENTAL
Intervention: Social capital measurement using Delaviz questionnaire
Number of subjects: 378
Study 33181328 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir combined with inhaled interferon beta-1b
Number of subjects: 89
Study 33181328 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 89
Study 32160298 — intervention group
Group type: COMPARATOR
Intervention: Calcium acetate
Number of subjects: 0
Study 32160298 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer carbonate
Number of subjects: 0
Study 32160298 — intervention group
Group type: COMPARATOR
Intervention: Lanthanum carbonate
Number of subjects: 0
Study 32160298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36200523 — intervention group
Group type: EXPERIMENTAL
Intervention: Diammonium glycyrrhizinate (DG) 150 mg three times a day combined with clarithromycin 250 mg once a day and isotretinoin 10 mg once every 2 days
Number of subjects: 0
Study 36200523 — intervention group
Group type: EXPERIMENTAL
Intervention: Diammonium glycyrrhizinate (DG) 150 mg three times a day combined with clarithromycin 500 mg once a day and isotretinoin 10 mg once a day
Number of subjects: 0
Study 36200523 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 500 mg once a day and isotretinoin 10 mg once a day
Number of subjects: 0